27 Aug 2019

Everstone Group makes significant investment in Translumina

  • Partnership aimed at scaling the business globally through organic growth and acquisitions

Mumbai, August 27, 2019 – The Everstone Group has made a significant investment to acquire a stake in Translumina. The proceeds from the investment will help Translumina accelerate the company’s growth and scale its operations globally.

Founded in Hechingen, Germany, Translumina is a leading global manufacturer and distributor of cardiac stents and cardiovascular medical devices. Translumina’s technologies were developed in collaboration with the German Heart Centre and are endorsed by the European Society of Cardiology. Translumina combines the best of German technology, intellectual property and high-quality standards with Indian capabilities of manufacturing innovative products at affordable prices.

Translumina benefits from end-to-end development and manufacturing capabilities of stent delivery systems in India and Germany. The company distributes its products in over 30 countries across Europe, Asia, Latin America and Middle East. Everstone’s partnership will help the Company to acquire global assets, augment the company’s research and development efforts, bolster its India manufacturing capabilities and enhance Translumina’s distribution ecosystem.

“We are excited to partner with Everstone group who possess the best expertise in the market today to guide young companies to become large multinationals. Everstone’s sectoral and international experience will help Translumina achieve its’ global ambition by strengthening our organization and systems while retaining our agility and entrepreneurial spirit to create strong footprints in healthcare market” said Gurmit Singh Chugh, Chairman of Translumina.

“Translumina is extremely well positioned to emerge as a global leader in stents and cardiovascular technologies at highly affordable prices. Everstone’s expertise in healthcare will help unlock the company’s full potential by scaling manufacturing, strengthening its global distribution and driving new product development” said Arjun Oberoi, Managing Director, Everstone Group.

About Everstone Group
Everstone is a premier investment group focused on India and South East Asia, with assets in excess of US$5 billion across private equity, real estate, green infrastructure and venture capital. Everstone has a significant resource base across its seven offices in Singapore, India (Mumbai, Delhi, Bangalore), London, New York and Mauritius, comprising best-of-breed investing, operations and strategic resources with significant experience and skills. For more information, visit www.everstonecapital.com

About Translumina
Translumina is a global developer and manufacturer of innovative cardiovascular medical devices used in interventional cardiology and minimally invasive surgery. It’s flagship products, YUKON® Choice PC, YUKON® Choice Flex, YUKON® Chrome PC and VIVO ESAR represent the 3rd generation drug eluting stents systems. Translumina is the only company in the world that has published 10-year safety and efficacy data for its Yukon Choice PC stent in a head-to-head study against Xience, a market-leading stent from Abbott, as per the ISAR-TEST 4 study presented at the 2018 American Heart Association meeting. In addition, the company markets a wide range of cardiovascular devices including coronary angioplasty balloons, structural heart disease products and cardiac assist devices. For more information, visit www.translumina.in and www.translumina.de